|
1
|
The Non-Hodgkin’s Lymphoma Pathologic
Classification Project. National Cancer Institute sponsored study
of classifications of non-Hodgkin’s lymphomas: summary and
description of a working formulation for clinical usage. Cancer.
49:2112–2135. 1982.
|
|
2
|
The International Non-Hodgkin’s Lymphoma
Prognostic Factors Project. A predictive model for aggressive
non-Hodgkin’s lymphoma. N Engl J Med. 329:987–994. 1993.
|
|
3
|
Tilly H and Zelenetz A: Treatment of
follicular lymphoma: current status. Leuk Lymphoma. 49(Suppl 1):
S7–S17. 2008. View Article : Google Scholar
|
|
4
|
Coiffier B, Lepage E, Briere J, et al:
CHOP chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med.
346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pfreundschuh M, Trumper L, Osterborg A, et
al: CHOP-like chemotherapy plus rituximab versus CHOP-like
chemotherapy alone in young patients with good-prognosis diffuse
large-B-cell lymphoma: a randomised controlled trial by the
MabThera International Trial (MInT) Group. Lancet Oncol. 7:379–391.
2006. View Article : Google Scholar
|
|
6
|
Sehn LH, Donaldson J, Chhanabhai M, et al:
Introduction of combined CHOP plus rituximab therapy dramatically
improved outcome of diffuse large B-cell lymphoma in British
Columbia. J Clin Oncol. 23:5027–5033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thieblemont C and Gisselbrecht C:
Second-line treatment paradigms for diffuse large B-cell lymphomas.
Curr Oncol Rep. 11:386–393. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cerny J, Trneny M, Slavickova A, et al:
Rituximab based therapy followed by autologous stem cell
transplantation leads to superior outcome and high rates of PCR
negativity in patients with indolent B-cell lymphoproliferative
disorders. Hematology. 14:187–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Philip T, Guglielmi C, Hagenbeek A, et al:
Autologous bone marrow transplantation as compared with salvage
chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s
lymphoma. N Engl J Med. 333:1540–1545. 1995.PubMed/NCBI
|
|
10
|
Flohr T, Hess G, Kolbe K, et al: Rituximab
in vivo purging is safe and effective in combination with
CD34-positive selected autologous stem cell transplantation for
salvage therapy in B-NHL. Bone Marrow Transplant. 29:769–775. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Magni M, Di NM, Devizzi L, et al:
Successful in vivo purging of CD34-containing peripheral blood
harvests in mantle cell and indolent lymphoma: evidence for a role
of both chemotherapy and rituximab infusion. Blood. 96:864–869.
2000.PubMed/NCBI
|
|
12
|
Hicks LK, Woods A, Buckstein R, et al:
Rituximab purging and maintenance combined with auto-SCT: long-term
molecular remissions and prolonged hypogammaglobulinemia in
relapsed follicular lymphoma. Bone Marrow Transplant. 43:701–708.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheson BD, Horning SJ, Coiffier B, et al:
Report of an international workshop to standardize response
criteria for non-Hodgkin’s lymphomas. NCI Sponsored International
Working Group. J Clin Oncol. 17:12441999.PubMed/NCBI
|
|
14
|
Haioun C, Lepage E, Gisselbrecht C, et al:
Survival benefit of high-dose therapy in poor-risk aggressive
non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2
protocol - a Groupe d’Etude des Lymphomes de l’Adulte study. J Clin
Oncol. 18:3025–3030. 2000.
|
|
15
|
Tarella C, Zanni M, Di NM, et al:
Prolonged survival in poor-risk diffuse large B-cell lymphoma
following front-line treatment with rituximab-supplemented,
early-intensified chemotherapy with multiple autologous
hematopoietic stem cell support: a multicenter study by GITIL
(Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia.
21:1802–1811. 2007.
|
|
16
|
Jacquy C, Soree A, Lambert F, et al: A
quantitative study of peripheral blood stem cell contamination in
diffuse large-cell non-Hodgkin’s lymphoma: one-half of patients
significantly mobilize malignant cells. Br J Haematol. 110:631–637.
2000.PubMed/NCBI
|
|
17
|
Goldberg S, Pecora A, Jennis A, et al:
Rituximab permits in vivo purging and collection of tumor-free stem
cells prior to autologous transplantation for B-cell non-Hodgkin’s
lymphoma. Blood. 94:141a1999.
|
|
18
|
Haioun C, Delrau-Larue M, Beaujean F, et
al: Efficiency of in vivo purging with rituximab before autologous
peripheral blood stem cell transplantation (PBSCT) in B-cell
non-Hodgkin’s lymphoma (NHL). Blood. 96:384a2000.PubMed/NCBI
|
|
19
|
Salles G, Moullet I, Charlot C, et al: In
vivo purging with rituximab before autologous peripheral blood
progenitor cell (PBPC) transplantation in lymphoma patients. Blood.
94:141a1999.
|
|
20
|
Mounier N, Gisselbrecht C, Briere J, et
al: All aggressive lymphoma subtypes do not share similar outcome
after front-line autotransplantation: a matched-control analysis by
the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol.
15:1790–1797. 2004.
|
|
21
|
Horwitz SM, Negrin RS, Blume KG, et al:
Rituximab as adjuvant to high-dose therapy and autologous
hematopoietic cell transplantation for aggressive non-Hodgkin
lymphoma. Blood. 103:777–783. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Habermann TM, Weller EA, Morrison VA, et
al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab
in older patients with diffuse large B-cell lymphoma. J Clin Oncol.
24:3121–3127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lim SH, Zhang Y, Wang Z, et al:
Maintenance rituximab after autologous stem cell transplant for
high-risk B-cell lymphoma induces prolonged and severe
hypogammaglobulinemia. Bone Marrow Transplant. 35:207–208. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishio M, Fujimoto K, Yamamoto S, et al:
Delayed redistribution of CD27, CD40 and CD80 positive B cells and
the impaired in vitro immunoglobulin production in patients with
non-Hodgkin lymphoma after rituximab treatment as an adjuvant to
autologous stem cell transplantation. Br J Haematol. 137:349–354.
2007. View Article : Google Scholar
|
|
25
|
Ghielmini M, Schmitz SF, Cogliatti S, et
al: Effect of single-agent rituximab given at the standard schedule
or as prolonged treatment in patients with mantle cell lymphoma: a
study of the Swiss Group for Clinical Cancer Research (SAKK). J
Clin Oncol. 23:705–711. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cartron G, Blasco H, Paintaud G, Watier H
and Le GC: Pharmacokinetics of rituximab and its clinical use:
thought for the best use? Crit Rev Oncol Hematol. 62:43–52. 2007.
View Article : Google Scholar : PubMed/NCBI
|
